Literature DB >> 29022518

Research on a 'drug-centred' approach to psychiatric drug treatment: assessing the impact of mental and behavioural alterations produced by psychiatric drugs.

J Moncrieff1.   

Abstract

AIMS: This article explores an alternative understanding of how psychiatric drugs work that is referred to as the drug-centred model of drug action. Unlike the current disease-centred model, which suggests that psychiatric drugs work by correcting an underlying brain abnormality, the drug-centred model emphasises how psychiatric drugs affect mental states and behaviour by modifying normal brain processes. The alterations produced may impact on the emotional and behavioural problems that constitute the symptoms of mental disorders.
METHODS: Arguments are put forward that justify the consideration of the drug-centred model. The research necessary to support the prescription of drugs according to such a model is explored.
RESULTS: Evidence from neurochemistry and comparative drug trials do not confirm the disease-centred model of drug action. Since psychiatric drugs are recognised to have mind- and behaviour-altering properties, the drug-centred model constitutes a plausible alternative. The drug-centred model suggests that research is needed to identify all the alterations produced by various sorts of drugs, both acute and long term, and how these might interact with the symptoms and problems associated with different mental disorders. This requires detailed animal and volunteer studies and data from patients prescribed drug treatment long term, along with placebo-controlled and comparative trials that look at the overall impact of drug-induced alterations on well-being and functioning as well as symptoms. Research is also needed on alternative ways of fulfilling the function of drug treatment. The moral aspect of using drugs to modify behaviour rather than treat disease needs honest and transparent consideration.
CONCLUSIONS: It is hoped this discussion will encourage the psychiatric and pharmaceutical research community to provide more of the information that is required to use psychiatric drugs safely and effectively.

Entities:  

Keywords:  Antidepressants; antipsychotics; drug mechanism of action; psychopharmacology; psychotropic drugs; research design and methods

Mesh:

Substances:

Year:  2017        PMID: 29022518      PMCID: PMC6998955          DOI: 10.1017/S2045796017000555

Source DB:  PubMed          Journal:  Epidemiol Psychiatr Sci        ISSN: 2045-7960            Impact factor:   6.892


  17 in total

1.  The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys.

Authors:  Karl-Anton Dorph-Petersen; Joseph N Pierri; James M Perel; Zhuoxin Sun; Allan R Sampson; David A Lewis
Journal:  Neuropsychopharmacology       Date:  2005-09       Impact factor: 7.853

Review 2.  Rethinking models of psychotropic drug action.

Authors:  Joanna Moncrieff; David Cohen
Journal:  Psychother Psychosom       Date:  2005       Impact factor: 17.659

3.  "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time.

Authors:  Anne-Noël Samaha; Philip Seeman; Jane Stewart; Heshmat Rajabi; Shitij Kapur
Journal:  J Neurosci       Date:  2007-03-14       Impact factor: 6.167

Review 4.  Initiation and adaptation: a paradigm for understanding psychotropic drug action.

Authors:  S E Hyman; E J Nestler
Journal:  Am J Psychiatry       Date:  1996-02       Impact factor: 18.112

Review 5.  A critique of the dopamine hypothesis of schizophrenia and psychosis.

Authors:  Joanna Moncrieff
Journal:  Harv Rev Psychiatry       Date:  2009       Impact factor: 3.732

6.  [Isolation and forced injection in the opinion of affected patients and patient care personnel. An accompanied quarter year sample].

Authors:  K Schmied; K Ernst
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1983

7.  The effects of tryptophan depletion on cognitive and affective processing in healthy volunteers.

Authors:  F C Murphy; K A Smith; P J Cowen; T W Robbins; B J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2002-07-13       Impact factor: 4.530

8.  Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia.

Authors:  Beng-Choon Ho; Nancy C Andreasen; Peg Nopoulos; Stephan Arndt; Vincent Magnotta; Michael Flaum
Journal:  Arch Gen Psychiatry       Date:  2003-06

9.  Can online consumers contribute to drug knowledge? A mixed-methods comparison of consumer-generated and professionally controlled psychotropic medication information on the internet.

Authors:  Shannon Hughes; David Cohen
Journal:  J Med Internet Res       Date:  2011-07-29       Impact factor: 5.428

10.  Do antidepressants cure or create abnormal brain states?

Authors:  Joanna Moncrieff; David Cohen
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

View more
  5 in total

1.  Safety of psychotropic medicines: contribution from observational evidence.

Authors:  H Verdoux
Journal:  Epidemiol Psychiatr Sci       Date:  2018-05-30       Impact factor: 6.892

2.  Esketamine clinical trials: reply to Maju et al.

Authors:  C Gastaldon; D Papola; G Ostuzzi; C Barbui
Journal:  Epidemiol Psychiatr Sci       Date:  2020-04-29       Impact factor: 6.892

3.  Esketamine for treatment resistant depression: a trick of smoke and mirrors?

Authors:  C Gastaldon; D Papola; G Ostuzzi; C Barbui
Journal:  Epidemiol Psychiatr Sci       Date:  2019-12-16       Impact factor: 6.892

4.  A parallel universe where psychiatry is like the rest of medicine.

Authors:  C M Pariante
Journal:  Epidemiol Psychiatr Sci       Date:  2017-12-04       Impact factor: 6.892

Review 5.  Do DSM classifications help or hinder
drug development?
.

Authors:  Michael Davidson; Cristian Gabos-Grecu
Journal:  Dialogues Clin Neurosci       Date:  2020-03       Impact factor: 5.986

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.